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We found thatmiR-96 is overexpressed in glioma, and its level inversely correlates with the survival
of patients. The reduction in miR-96 abundance suppresses the proliferation and colony formation
of glioma cells. The tumorigenicity of U-87 MG cells is reduced by miR-96 silencing. miR-96 contrib-
utes to the activation of Wnt/b-catenin pathway in glioma cells. HMG-box transcription factor 1
(HBP-1), a Wnt/b-catenin pathway inhibitor, is suppressed by miR-96. The reactivation of Wnt/b-
catenin signaling causes an increase in the proliferation of glioma cells, and a decrease in miR-96
expression. On the other hand, HBP1 silencing promotes miR-96 expression. Collectively, miR-96
contributes to the progression of glioma by enhancing the activation of the Wnt/b-catenin pathway,
and the miR-96/HBP1/Wnt/b-catenin regulatory circuitry promotes the proliferation of glioma cells.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Glioma is one of the most common types of malignant intracra-
nial tumors, and accounts for higher than 80% of tumors in brain
[1]. However, the molecular mechanisms of occurrence, progres-
sion and invasion of glioma have not been completed elucidated
yet.
miRNAs belong to non-coding RNA with a length of 20–22
nucleotides, and are widely distributed in a variety of organisms.
miRNAs degrade target mRNAs or inhibit their translation by bind-
ing their 30 untranslated region (30UTR) [2]. The association of miR-
NAs with the progression of cancers has been well demonstrated
by numerous studies [3]. Glioma-related miRNAs serving as onco-
genes or tumor suppressors include, but not limited to, miR-21
[4,5], miR-26b [6] and let-7 [7].
miR-96 was found to be overexpressed in some types of cancers
[8,9], and promote cancer progression by increasing the activity of
some essential molecular pathways such as KRAS [10]. However,
the association of miR-96 with glioma has not been veriﬁed yet.
Since miR-182/miR-183/miR-96 cluster has been conﬁrmed to be
overexpressed in medulloblastomas [11], we hypothesized that
miR-96 may play a role in brain cancers, such as glioma.In this study, we collected a set of glioma specimen from
patients, in which the expression proﬁle of miR-96 was detected.
Furthermore, the role of miR-96 in glioma and its involved mecha-
nism was also investigated.
2. Materials and methods
2.1. Cell cultures
Human glioma cell lines, U-87 MG, U-251 MG, U-373 MG and
M059J were purchased from American Type Culture Collection
(Manassas, VA). HEK-293T cells were obtained from Shanghai Cell
Collection (Shanghai, China). The cells were all cultured using
DMEM supplemented with 10% fetal bovine serum (FBS), 4 mM
glutamine, 100 units/ml penicillin, and 100 lg/ml streptomycin
in a 5% CO2 and humidiﬁed atmosphere at 37 C.
2.2. Glioma specimen
Malignant glioma and their corresponding non-cancerous brain
tissues were used in our study. The tissues were obtained from the
glioma patients with their written informed consent following the
procedures approved by Ethical Review Board in the Afﬁliated Hos-
pital of Medical College of Qingdao University (Qingdao, China).
These patients were subjected to surgery at Department of Neuro-
logical Surgery, The Afﬁliated Hospital of Medical College of Qing-
dao University (Qingdao, China).
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To get primary astrocyte culture, aborted fetus was obtained
from pregnant women with their written informed consent,
according to the previously published procedures approved by Eth-
ical Review Board in the Afﬁliated Hospital of Medical College of
Qingdao University (Qingdao, China). The procedures were brieﬂy
described as follows. Brain tissue from anterior fontanelle was
cut into pieces, and then, meninges were removed. Subsequently,
trypsin digestion was performed to get separate cells. The cells
were ﬁltered with steel net and cultured in DMEM supplemented
with 15% FBS. GFAP expression was conﬁrmed using immunoﬂuo-
rescent staining.2.4. qPCR assay
The protocols of qPCR assays were described previously [12].
Brieﬂy, total RNA were extracted from glioma tissues, matched
normal brain, glioma cell lines and normal astrocytes, using Trizol
solution (Sigma Aldrich) following manufacturer’s instructions. For
the detection ofmiR-96 levels in the parafﬁn-ﬁxed glioma sections,
a parafﬁn-ﬁxed tissue RNA extraction kit was employed (Beinuo
Life Science, China). Reverse transcription reaction was done with
All-in-One™ First-Strand cDNA Synthesis Kit (AORT-0020, GeneCo-
poeia) according to the manufacturer’s protocols. Quantitative PCR
(qPCR) assay was performed with All-in-One™ miRNA qRT-PCR
Detection Kit (AOMD-Q020, GeneCopoeia) with CFX96™ Real-Time
PCR Detection System supplied with analytical software (Bio-Rad).
U6 was selected as endogenous reference. The primers and probes
for miR-96 and U6 were obtained from GeneCopoeia.
To determine the mRNA levels of Axin2, CD44 and Lgr5, total
RNA was transcribed into cDNAs with Rever Tra Ace qPCR RT Kit
(Toyobo, Japan) following the manufacturer’s instructions. cDNA
was ampliﬁed by PCR, followed by agarose gel electrophoresis.
The involved primers are as follows: Axin2 forward: 50-CCGGTGG
ACCAAGTCCTTAC-30; Axin2 reverse: 50-TCCATTGCAGGCAAACCA-
GA-30; CD44 forward: 50-AGTCCCTGGATCACCGACAG-30; CD44
reverse: 50-GTTTCTTGCCTCTTGGTTGCT-30; Lgr5 forward: 50-TGAAC
ACCTGCTTGATGGCT-30; Lgr5 reverse: 50-TGCTGCGATGACCCCAAT-
TA-30; HBP-1 forward: 50-CTTGCCTTATCCGTGCAGGT-30; HBP-1
reverse: 50-GCCTGAGATTTCGACTTGCC-30; GAPDH forward: 50-TCA
GTGGTGGACCTGACCTG-30; GAPDH reverse: 50-TGCTGTAGCCAAAT
TCGTTG-30.
2.5. Northern blotting assay
Northern blotting assay was used to detect the expression level
of miR-96 in astrocyte and glioma cells following the procedures
previously described [13]. Brieﬂy, total RNA was extracted from
astrocyte and glioma cells using Trizol solution (Invitrogen), and
then, separated on a 15% urea-PAGE gel. The blots were transferred
onto positively charged nylon membranes (GE Healthcare Life
Sciences), followed by UV cross-linking. RNA blots were hybridized
with DIG-labeledmiR-96 or U6 probe (Exiqon, Denmark) overnight.
Membranes were then washed with a low-stringency buffer. DIG
Luminescent Detection Kit (Roche) was employed to examine
miR-96 abundance according to the manufacturer’s instructions.
2.6. miR-96 inhibitor
A mirVana™ miRNA inhibitor, which are single stranded RNAs
designed to bind and suppress speciﬁc endogenous miRNA, were
applied for silencing endogenous miR-96 expression (Invitrogen).
U-87 MG and U-251 MG cells were transfected with mirVana™
miRNA inhibitors (30 nM) for miR-96 or control molecules(30 nM) with Lipofectamine™ 2000 (Invitrogen), followed by sub-
sequent experiments.
2.7. Cell viability assessment
5  103 U-87 MG and U-251 MG cells were seeded into each
well of 96-well plates. Overnight, cells were subjected to the indi-
cated treatments. At the indicated time points, cells were treated
with 10 lL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) (5 mg/mL) for 4 h. MTT was then removed and
150 lL DMSO was replaced. The spectrophotometric absorbance
was detected on a model 550 microplate reader at 570 nm with a
reference wavelength of 655 nm. Cell viability was calculated as
the following formula: Viability (%) = absorbance value of adenovi-
rus-infected cells/absorbance value of control cells.
2.8. Cell cycle analysis
The procedures of cell cycle analysis were previously described
[14]. Brieﬂy after 48 h treatment, 2  105 cells were ﬁxed with cold
70% ethanol, and then treated with RNase A. Finally, cells were
incubated with propidium iodide (50 mg/mL), and then subjected
to ﬂow cytometry (FACSAria™ II, BD Biosciences). The percentages
of population in G0/G1, S and G2/M phases were quantiﬁed using
Modtif software.
2.9. Immunoblot assay
Total proteins were extracted from cells using M-PERMamma-
lian Protein Extraction Reagent (Thermo Scientiﬁc), and nuclear
extract was obtained by using the Qproteome Nuclear Protein Kit
(QIAGEN), according to the manufacturer’s instruction. The above
proteins were then separated using polyacrylamide gel electropho-
resis, and transferred onto 0.45 lm nitrocellulose membranes. The
membrane was blocked with 5% fat-free milk, and then incubated
with primary antibodies. Overnight, PBS with 0.5% Tween-20 was
used to wash the membrane, followed by incubation with appro-
priate secondary antibodies. The involved primary antibodies were
Ki-67, total b-catenin antibody, phosphorylated b-catenin anti-
body, HBP1 and GAPDH antibody (Cell Signaling Technology).
2.10. Animal experiments
The procedures of animal experiment were approved by Com-
mittee on the Use and Care on Animals in the Afﬁliated Hospital
of Medical College of Qingdao University (Qingdao, China). U-87
MG glioma xenograft was established by injecting 5  106 cells
into the ﬂanks of 4–5 weeks-old male BALB/c nude mice (Shanghai
Laboratory Animal Center, Shanghai, China). Twelve mice were
divided into 2 groups (n = 6). miR-96 inhibitors or control mole-
cules were directly injected into the tumors. Tumor diameters
were then periodically measured with calipers. Tumor volume
(mm3) = maximal length (mm)  (perpendicular width (mm))2/2.
Luciferase-marked U-87 MG tumor xenograft was established
by injecting luciferase-expressing U-87 MG cells into the forebrain
of 5-weeks-old male BALB/c nude mice (Shanghai Laboratory Ani-
mal Center, Shanghai, China) with the direction of a guide-screw.
U-87 MG cells expressing luciferase were established in Highene
Biotechnology Company (Qingdao, China). 22 mice were randomly
divided into 2 groups with the same size (n = 11).miR-96 inhibitors
or control molecules were directly injected into the formed tumors
with the help of a guide-screw. The deaths of mice were recorded
for survival curve using SPSS software. Live luciferase imaging was
performed using a non-invasive ChemiPro imaging system (Roper
Scientiﬁc), 15 days after intratumoral injection of miR-96 inhibi-
tors. Mice were anesthetized with isoﬂurane inhalation, followed
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nescent signals were acquired and then analyzed with ImageTool
3.0 (University of Texas Health Science Center) and Photoshop 7.0.
2.11. TOPﬂash assay
The activation of endogenous Wnt/b-catenin signaling was
examined by TCF reporter dual luciferase assay according to previ-
ous procedures [15]. Brieﬂy, cells were planted in each well of
24-well plates, and transfected with TCF reporter vector (TOPﬂash)
(Millipore) as well as renilla luciferase reporter vector (40:1) (Pro-
mega) with Lipofectamine™ 2000 (Invitrogen). Overnight, cells
were subjected to the indicated treatments. 48 h Later, cells
were collected and detected for luciferase expression with dual-
luciferase reporter assay kit on a luminometer (Promega), as rec-
ommended by the manufacturer.
2.12. miR-96 target prediction and veriﬁcation
The potential miR-96 targets were predicted using the algo-
rithms TargetScan (http://www.targetscan.org/). HBP1 was among
the list of predicted miR-96 targets. To conﬁrm HBP1 as a bona ﬁde
miR-96 target, a luciferase reporter vector that contained a 210 bp
DNA construct identical to part of HBP1 30UTR harboring potential
miR-96 binding site (GTGCCAA) were inserted into pMIR-REPORT
vector (Applied Biosystems) to get luc-HBP13UTR. A luciferase vec-
tor containing mutant miR-96 binding site (GTGCGTA) was gener-
ated and used as control. After miR-96 mimics was transfected
into HEK-293T cells with Lipofectamine™ 2000 (Invitrogen), detec-
tion of luciferase activity was performed with Dual-Luciferase
Reporter Assay kit (Promega, WI) according to manufacturer’
instructions.
2.13. HBP1 siRNA and overexpression vectors
We employed HBP1 siRNA and plasmid expressing HBP1 to
reduce and increase the expression levels of HBP1 in cells, respec-
tively. Small interfering RNA (siRNA) for HBP1 was purchased for
Shanghai Genepharma Co. Ltd. BHP1 siRNA (10 ng/mL) was
co-transfected into cells together withmiR-96 inhibitors or control.
48 h Later, the cells were subjected to the subsequent experiments.
pcDNA3.1-HBP1, an eukaryotic expression vector for HBP1, was
purchased from Highene Biotechnology Company (Qingdao,
China), as well as pcDNA3.1-GFP as control. 1 ng pcDNA3.1-HBP1
or pcDNA3.1-GFP was transfected into astrocyte with Lipofect-
amine™ 2000 (Invitrogen). 48 h Later, the cells were subjected to
the subsequent experiments.
2.14. Statistical analysis
Two-tailed student’s test was used for statistical analysis in our
study. ⁄ Means signiﬁcant (P < 0.05) and ⁄⁄ means very signiﬁcant
(P < 0.01).
3. Results
3.1. Glioma expressed higher level of miR-96 than normal brain tissue
First of all, we employed qPCR assays to detect miR-96 expres-
sion levels in glioma specimen. The data revealed that miR-96 lev-
els were increased in glioma samples by 106.7%, in comparison
with non-cancerous brain tissue (n = 24, P < 0.01) (Fig. 1A). miR-
96 was also found to be overexpressed in glioma cell lines, U-87
MG, U-251 MG, U-373 MG and M059J (P < 0.01) (Fig. 1B). Further-
more, we used northern blotting to conﬁrm the difference in theexpression proﬁle of miR-96 between glioma cell lines and normal
astrocyte (Fig. 1C).
3.2. miR-96 levels were inversely correlated with the survival
of glioma patients
Then, we detected miR-96 expression levels in a panel of paraf-
ﬁn-ﬁxed glioma section from the patients, who underwent surgery
5 or more years ago. The correlation between miR-96 levels and
survival time of these patients were analyzed with SPSS analytical
software. The results revealed that miR-96 levels were inversely
correlated with the survival time of selected patients (R = 0.512,
P < 0.05) (Fig. 1D). The correlation between miR-96 levels and his-
tological features of these glioma tissues was also shown in
Table 1.
3.3. The suppression of miR-96 expression affected the proliferation
of glioma cells
Subsequently, we investigated if the reduction in miR-96 level
inﬂuenced the proliferation of glioma cells. We used speciﬁc syn-
thetic inhibitors to silence the expression of endogenous miR-96
(Fig. 2A). MTT assays revealed that the proliferation rates of U-87
MG and U-251 MG cells were both reduced when endogenous
miR-96 level was reduced by miRNA inhibitors (Fig. 2B). Flow cyto-
metric analysis of cell cycle distribution demonstrated that miR-96
silencing led to an elevation in the percentages of G0/G1 popula-
tion, and a decline in the percentage of S or/and G2/M population
(Fig. 2C and D). Immunoblot assays also showed that the expres-
sion of Ki-67, a biomarker indicating accelerated proliferation,
was inhibited in U-87 MG and U-251 MG cells by suppressing
miR-96 (Fig. 2E).
3.4. miR-96 knockdown impaired the tumorigenecity of glioma cells
in vivo
Next, we silenced the expression of miR-96 in U-87 MG glioma
cells, followed by incubating these cells into the ﬂanks of nude
mice. Periodical measurement of tumor volumes revealed that
miR-96 downregulation was able to reduce the growth of glioma
in mice (Fig. 3A and B). Furthermore, we injected luciferase-
expressing U-87 MG cells into the brains of another group of mice.
The survival of mice with miR-96 silencing is longer than controls
(Fig. 3C). The imaging consistently indicated that miR-96 downreg-
ulation retarded orthotopic growth of glioma in vivo (Fig. 3D).3.5. miR-96 downregulation suppressed the activation of Wnt/b-
catenin pathway in a b-catenin-independent way
Considering that Wnt/b-catenin pathway plays a critical role in
the growth and progression of glioma, we subsequently studied
the inﬂuence of decreased miR-96 expression on Wnt/b-catenin
signaling. TOPﬂash assays showed that the activation of Wnt/b-
catenin pathway was greatly suppressed by miR-96 downregula-
tion (Fig. 4A). Reverse transcription PCR assay also conﬁrmed that
target genes of Wnt/b-catenin signaling, such as Axin2, CD44 and
Lgr5, had reduced mRNA levels when miR-96 was silenced
(Fig. 4B). However, Immunoblot assays revealed that the phos-
phorylation of b-catenin was not changed in U-87 MG and U-251
MG cells transfected with miR-96 inhibitor, as well as the levels
of nuclear b-catenin accumulation (Fig. 4C). This unexpected ﬁnd-
ing implied that miR-96 affected Wnt/b-catenin pathway in a
b-catenin-independent mechanism. We hypothesized that miR-96
may target a Wnt pathway component downstream of b-catenin,
the key transcription factor in this signaling.
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Fig. 1. miR-96 overexpression was associated with the prognosis of glioma. (A) miR-96 expression levels were determined by qPCR assays in glioma specimen and matched
normal brain tissues (n = 24). The lines represented the average values. N, normal brain tissues; T, glioma. (B) miR-96 abundance was assessed by qPCR assays in normal
astrocyte and glioma cell lines, U-87 MG, U-251 MG. U-373 MG and M059J. The bars showed means ± SD of three independent experiments. (C) Northern blot assay was used
to conﬁrm the expression proﬁle ofmiR-96 in the above cell lines. U6was used as endogenous references. (D) The correlation between miR-96 levels and patient survival was
analyzed using SPSS software (n = 37). ⁄⁄P < 0.01.
Table 1
Histological features of glioma tissues.
Pathologic variable miR-96 P value
Low (n = 18) High (n = 19)
Tumor grading
I 2 0 0.0315
II 4 1
III 7 7
IV 5 11
Invasion
 4 0 0.0088
+ 14 19
Proliferation
 2 0 0.0217
+ 8 6
++ 8 13
Low and high miR-96 groups are deﬁned as 19 patients with the highest miR-96
expression and 18 patients with lowest miR-96 levels, respectively (n = 37).
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inhibitor, in glioma cells
To further explore the mechanism by which miR-96 affected
Wnt/b-catenin pathway, we used online database to predict itstarget genes that are associated with Wnt/b-catenin signaling. A
potential miR-96 seed sequence was found to be located within
3’UTR of HBP1 mRNA (Fig. 5A). To conﬁrm the inhibitory effect of
miR-96 on HBP1 expression, we constructed luciferase expression
vectors harboring wild type or mutant HBP1 30UTR, (luc-HBP1-
3UTR and luc-HBP1-3UTR-M, respectively). Luciferase assay
revealed that luc-HBP1-3UTR had lower activity than luc-HBP1-
3UTR-mut in HEK-293T cells when synthetic miR-96 was transfec-
ted (Fig. 5B). Also, the abundance of HBP1 protein was greatly
increased by miR-96 suppression in glioma cell lines (Fig. 5C). Fur-
thermore, we found that there was an inverse correlation in glioma
specimen between the levels of miR-96 and HBP1 (R = 0.852,
P < 0.01, n = 10) (Fig. 5D). It should be noted that HBP1 suppresses
the activation of Wnt/b-catenin signaling by antagonizing the tran-
scriptional activity of b-catenin on its target gene, rather than
destabilizing b-catenin or reducing its nuclear accumulation.
3.7. The suppression of HBP1 mediated the inhibitory effect of miR-96
on Wnt/b-catenin pathway
To conﬁrm if the regulatory effect ofmiR-96 on HBP1 expression
accounts for its effect on the activation of Wnt pathway, we trans-
fected a small interfering RNA (siRNA) speciﬁc for HBP1 into
glioma cells where miR-96 expression level was reduced
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3044 Z. Yan et al. / FEBS Letters 588 (2014) 3038–3046(Fig. 6A). The results indicated that there was no signiﬁcant differ-
ence in TOPﬂash activity between control and U-87 MG cells co-
transfected with miR-96 inhibitor and HBP1 siRNA (Fig. 6B). Also,
transcriptional levels of Wnt pathway target genes were found to
be increased in miR-96-silencing glioma cells by HBP1 siRNA
(Fig. 6C). The above data suggested that the suppression of HBP1
expression was able to rescue the effect of miR-96 downregulation
on Wnt/b-catenin pathway.
3.8. The increase in HBP1 expression was required for the effect of miR-
96 silencing on glioma cell proliferation
To conﬁrm the role of HBP1 in the effect of miR-96 on glioma
cell proliferation, we transfected HBP1 siRNA into U-87 MG cells
together with miR-96 inhibitor or not. MTT assays revealed that
reducing HBP1 was able to abolish the inhibitory effect of miR-96
suppression on the proliferation rate of glioma cells (Fig. 6D). Fur-
thermore, ﬂow cytometry also indicated that G0/G1 arrest was res-
cued in miR-96-silencing glioma cells by HBP1 siRNA (Fig. 6E and
F). Collectively, HBP1 overexpression is indispensible for reduced
proliferation of glioma cells induced by miR-96 downregulation.
3.9. HBP1 silencing promoted Wnt/b-catenin-dependent miR-96
expression
Given that Wnt/b-catenin can promote miR-96 expression in
gastric cancer cells [16], we wanted to determine if HBP1 could
affect the expression of miR-96 in glioma cells. qPCR and northernblot assays both indicated that HBP1 siRNA increased the expres-
sion level of miR-96 in glioma cells under the treatment of miR-
96 inhibitor (Fig. 7A and B). Furthermore, the expression of endog-
enous miR-96 was also reduced in primary astrocyte transfected
with a HBP1-expressing vector, in comparison with control vec-
tor-transfected one (Fig. 7C and D).4. Discussion
miR-96 has been reported to be associated with some types of
cancers, such as colorectal carcinoma [8], hepatocellular carcinoma
[17], breast cancer [9], prostate carcinoma [18], endometrial cancer
[19], pancreatic carcinoma [20], and non-small cell lung cancer
[21]. However, the implication of this oncogenic miRNA in brain
cancers has not been uncovered yet. For the ﬁrst time, we provided
evidence that miR-96 contributes to the unlimited proliferation of
glioma, both in vitro and vivo. Also, miR-96 expression proﬁle in
malignant glioma can also be used to predict the prognosis of
patients.
Wnt/b-catenin pathway plays a critical role in glioma progres-
sion [22]. Previous studies showed that glycogen synthase kinase
3 beta (GSK3b) suppression of Wnt/b-catenin pathway reduced
miR-96 expression [16]. However, the effect of miR-96 on Wnt/b-
catenin signaling has not been studied yet. In this study, we
employed glioma cells as experimental models to explore if the
change in miR-96 expression can affect the activation of Wnt path-
way. The results showed that the overexpression of this oncogenic
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glioma cells. Based on the above ﬁndings, we proposed that there
is amiR-96/HBP1/Wnt/b-catenin regulatory circuitry, at least in gli-
oma cells (Fig. 7E).
The target genes of miR-96 that have been experimentally iden-
tiﬁed by previous researches included FOXO1 [9,19], FOXO3a [23],
RAD51 [24], REV1 [24], and RECK [21]. However, regulatory com-
ponents of Wnt/b-catenin pathway have not been identiﬁed to be
on the list of miR-96 target genes. Our work demonstrated that
HBP1, a negative regulator of Wnt pathway downstream of
GSK3b/b-catenin complex, is a target gene of miR-96, and accounts
for the effect ofmiR-96 on glioma cell proliferation. Although some
other miRNAs have been shown to suppress the expression of
HBP1 [25,26], we established the regulatory relationship between
miR-96 and HBP1.
HBP1 is a tumor suppressor for many types of cancer. For
instances, HBP1 was found to mediate the suppressing effect of
N-acetylcysteine on the growth of oral cancer [27]. It has also been
demonstrated that HBP1 is associated with invasive breast cancer
in a Wnt pathway-dependent mechanism. In the present study,
we established the relevance of HBP1 with glioma cells. This is
the ﬁrst time, to our knowledge, to provide evidence supporting
the role of HBP1 in glioma progression.
Taken together, we demonstrated that miR-96, which is overex-
pressed in glioma specimen and cell lines, contributed to theproliferation of glioma cells, by enhancing Wnt/b-catenin pathway
in a HBP1-dependent manner.
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